These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1575773)

  • 1. CD4(81-92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro.
    Rausch DM; Lifson JD; Padgett MP; Chandrasekhar B; Lendvay J; Hwang KM; Eiden LE
    Biochem Pharmacol; 1992 Apr; 43(8):1785-96. PubMed ID: 1575773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents.
    Rausch DM; Hwang KM; Padgett M; Voltz AH; Rivas A; Engleman E; Gaston I; McGrath M; Fraser B; Kalyanaraman VS
    Ann N Y Acad Sci; 1990; 616():125-48. PubMed ID: 2078014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.
    Nara PL; Hwang KM; Rausch DM; Lifson JD; Eiden LE
    Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7139-43. PubMed ID: 2789382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity.
    Lifson JD; Hwang KM; Nara PL; Fraser B; Padgett M; Dunlop NM; Eiden LE
    Science; 1988 Aug; 241(4866):712-6. PubMed ID: 2969619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation.
    Kalyanaraman VS; Rausch DM; Osborne J; Padgett M; Hwang KM; Lifson JD; Eiden LE
    J Immunol; 1990 Dec; 145(12):4072-8. PubMed ID: 1701782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
    Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A
    Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity.
    Lee-Huang S; Maiorov V; Huang PL; Ng A; Lee HC; Chang YT; Kallenbach N; Huang PL; Chen HC
    Biochemistry; 2005 Mar; 44(12):4648-55. PubMed ID: 15779891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic peptides allow discrimination of structural features of CD4(81-92) important for HIV-1 infection versus HIV-1-induced syncytium formation.
    Lifson JD; Rausch DM; Kalyanaraman VS; Hwang KM; Eiden LE
    AIDS Res Hum Retroviruses; 1991 Jun; 7(6):521-7. PubMed ID: 1931230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death.
    Callebaut C; Jacotot E; Guichard G; Krust B; Rey-Cuille M; Cointe D; Benkirane N; Blanco J; Muller S; Briand J; Hovanessian AG
    Virology; 1996 Apr; 218(1):181-92. PubMed ID: 8615021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
    Medinas RJ; Lambert DM; Tompkins WA
    J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and CD4 binding studies of a fluorescent analogue of a peptide that enhances HIV-1 infectivity.
    Dettin M; Scarinci C; Zanotto C; Cabrelle A; De Rossi A; Di Bello C
    J Pept Res; 1998 Feb; 51(2):110-5. PubMed ID: 9516045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A synthetic peptide "T22" as anti-HIV agents].
    Nakashima H; Murakami T
    Nihon Rinsho; 1993 Sep; 51 Suppl():146-52. PubMed ID: 8271378
    [No Abstract]   [Full Text] [Related]  

  • 13. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
    Wild C; Oas T; McDanal C; Bolognesi D; Matthews T
    Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism.
    De Rossi A; Pasti M; Mammano F; Panozzo M; Dettin M; Di Bello C; Chieco-Bianchi L
    Virology; 1991 Sep; 184(1):187-96. PubMed ID: 1871966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
    Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
    Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.
    Zhang X; Gaubin M; Briant L; Srikantan V; Murali R; Saragovi U; Weiner D; Devaux C; Autiero M; Piatier-Tonneau D; Greene MI
    Nat Biotechnol; 1997 Feb; 15(2):150-4. PubMed ID: 9035140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
    Rivier J; Lahrichi SL; Gulyas J; Erchegyi J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W
    J Med Chem; 1998 Jul; 41(14):2614-20. PubMed ID: 9651165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased anti-HIV-1 activity of CD4 CDR3-related synthetic peptides by scrambling and further structural modifications, including D-isomerization and dimerization.
    Kumagai K; Tokunaga K; Tsutsumi M; Ikuta K
    FEBS Lett; 1993 Sep; 330(2):117-21. PubMed ID: 7689978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41.
    Tan J; Su M; Zeng Y; Wang C
    Bioorg Med Chem; 2016 Jan; 24(2):201-6. PubMed ID: 26706116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gold(I) complex of 1,1'-bis(diphenylphosphino) ferrocene-quinoline conjugate: a virostatic agent against HIV-1.
    Gama N; Kumar K; Ekengard E; Haukka M; Darkwa J; Nordlander E; Meyer D
    Biometals; 2016 Jun; 29(3):389-97. PubMed ID: 26922346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.